Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis

Table 5 Comparison of complications rate in the studied groups

Parameter	Dapagliflozin, n = 200	Control group, n = 100	Test of sig.
			χ²	P value
UTI	0 (0)	19 (19)	40.569	0.0001
Proteinuria	0 (0)	0 (0)
Frequent micturition	20 (10)	0 (0)	10.714	0.001
Vertigo	20 (10)	0 (0)	10.714	0.001
Hepatic encephalopathy	0 (0)	6 (6)	6.091	0.014
Variceal bleeding	0 (0)	13 (13)	13.437	0.002
HCC	0 (0)	0 (0)
Pyelonephritis	0 (0)	0 (0)
Hypoglycemia	0 (0)	5 (5)	10.169	0.0001
Genital infection	8 (4)	4 (4)	0.098	0.755
Syncope	0 (0)	0 (0)
Hypotension	12 (6)	5 (5)	0.125	0.724
Dehydration	12 (6)	5 (5)	0.125	0.724
Abdominal discomfort	0 (0)	0 (0)
Back pain	0 (0)	0 (0)
Dizziness	0 (0)	0 (0)
Rash	0 (0)	0 (0)
Phlebitis	0 (0)	0 (0)

Data are n (%). HCC: Hepatocellular carcinoma; UTI: Urinary tract infection.